Global Preimplantation Genetics Diagnosis (PGD) Market Size By Type (Gender Selection, Chromosomal Abnormalities), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Preimplantation Genetic Diagnosis (PGD) Market was valued at USD 89.5 million in 2023 and is projected to reach USD 162.4 million by 2031, expanding at a CAGR of 7.6% during the forecast period (2023–2031). PGD is increasingly adopted across fertility clinics and genetic laboratories due to its ability to detect genetic abnormalities before embryo implantation, thereby preventing hereditary disorders. The market is witnessing robust growth driven by increasing infertility rates, rising demand for IVF procedures, advancements in reproductive genetics, and the rising preference for early disease diagnosis and prevention among prospective parents.

Drivers

1. Rising Incidence of Genetic Disorders

The growing prevalence of inherited diseases like cystic fibrosis, Tay-Sachs disease, and thalassemia is boosting the demand for PGD. Couples with known genetic risks are increasingly opting for PGD to ensure healthier offspring.

2. Growth in Assisted Reproductive Technology (ART)

As more couples turn to ART due to delayed childbearing and infertility issues, PGD becomes an essential part of IVF cycles for those with a history of genetic disease or recurrent miscarriage.

3. Technological Advancements in Genetic Testing

Innovations such as next-generation sequencing (NGS), array comparative genomic hybridization (aCGH), and real-time PCR are enhancing the accuracy and efficiency of PGD procedures.

Restraints

1. Ethical and Legal Concerns

The use of PGD for non-medical reasons, such as gender selection, raises ethical debates. Additionally, legal restrictions in certain countries can limit market penetration.

2. High Cost and Limited Accessibility

PGD procedures add significant cost to IVF cycles, making them less accessible in low-income regions. Insurance coverage limitations further restrict broader adoption.

Opportunity

1. Expanding Medical Tourism and Fertility Clinics

Countries like India, Thailand, and Mexico are becoming global hubs for fertility treatments, creating new opportunities for PGD services.

2. Personalized Reproductive Care

The trend toward personalized medicine is encouraging tailored fertility solutions, including genetic screening before embryo implantation to enhance success rates and reduce risks.

Market by System Type Insights

The Next-Generation Sequencing (NGS) segment held the largest share in 2023 and is expected to dominate throughout the forecast period. NGS enables high-throughput, accurate detection of single-gene disorders, chromosomal translocations, and aneuploidies, making it the preferred system in modern fertility centers.

Market by End-use Insights

Fertility Clinics represented the leading end-use segment in 2023, accounting for over 60% of the market share. With the increasing number of IVF procedures globally, fertility clinics are primary adopters of PGD, ensuring safer pregnancies and improved IVF success rates. Genetic diagnostic laboratories are also gaining traction due to the growing focus on precision diagnostics.

Market by Regional Insights

North America led the global PGD market in 2023, supported by a well-established healthcare infrastructure, high adoption of ART, and favorable reimbursement policies in the U.S. and Canada. Meanwhile, Asia-Pacific is projected to witness the fastest growth during the forecast period due to rising infertility rates, increasing medical tourism, and expanding fertility treatment infrastructure.

Competitive Scenario

Key players in the global PGD market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Natera, Inc., Invitae Corporation, Genesis Genetics, and Bioarray SL. These companies are focused on R&D for enhancing the accuracy of genetic screening, expanding their service offerings, and forming strategic partnerships with fertility centers to broaden their customer base.

Scope of Work – Global Preimplantation Genetic Diagnosis (PGD) Market

Key Market Developments

2023: Illumina, Inc. launched a new NGS-based PGD panel designed for comprehensive embryo analysis, improving diagnostic accuracy and reducing turnaround time.

2024: CooperSurgical announced a strategic partnership with major fertility centers in Asia to offer integrated PGD services.

2025: Natera, Inc. received regulatory approval for its AI-based PGD platform that enables real-time embryo screening, enhancing IVF outcomes.

FAQs

1. What is the current market size of the Global Preimplantation Genetic Diagnosis (PGD) Market?

The market was valued at USD 89.5 million in 2023.

2. What is the major growth driver of the Global Preimplantation Genetic Diagnosis (PGD) Market?

The increasing incidence of genetic disorders and growing adoption of ART are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Preimplantation Genetic Diagnosis (PGD) Market?

North America is expected to maintain the largest market share due to advanced healthcare infrastructure and high adoption rates.

4. Which segment accounted for the largest market share in Global Preimplantation Genetic Diagnosis (PGD) Market?

The Next-Generation Sequencing (NGS) system type segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Preimplantation Genetic Diagnosis (PGD) Market?

Key players include Illumina, Thermo Fisher Scientific, CooperSurgical, Natera, and PerkinElmer.